Stock BIO BIO-RAD LABORATORIES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Bio-Rad Laboratories, Inc.

Equities

BIO

US0905722072

Real-time Estimate Cboe BZX
Other stock markets
 11:55:00 2024-04-25 am EDT 		5-day change 1st Jan Change
275 USD -1.15% Intraday chart for Bio-Rad Laboratories, Inc. -2.26% -14.94%
Apr. 15 Zacks Investment Research Lowers Price Target on Bio-Rad Laboratories to $285 From $322 MT
Apr. 11 Oncocyte Corporation and Bio-Rad Laboratories, Inc. Partner on Global Launch of Transplant Assay CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

  • The company returns high margins, thereby supporting business profitability.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The company appears to be poorly valued given its net asset value.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • According to forecast, a sluggish sales growth is expected for the next fiscal years.
  • The company is highly valued given the cash flows generated by its activity.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
BIO-RAD LABORATORIES, INC. Stock Bio-Rad Laboratories, Inc.
-14.94% 7.94B
B-
ABBOTT LABORATORIES Stock Abbott Laboratories
-3.19% 185B
C+
MEDTRONIC PLC Stock Medtronic plc
-3.93% 107B
C
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-5.02% 67.55B
A
DEXCOM, INC. Stock DexCom, Inc.
+9.63% 54.6B
B-
CENCORA, INC. Stock Cencora, Inc.
+17.03% 47.42B
B-
HOYA CORPORATION Stock Hoya Corporation
+3.86% 42.24B
B+
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+4.85% 28.24B
A-
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+0.44% 26.42B
B
TERUMO CORPORATION Stock Terumo Corporation
+12.40% 25.66B
A-
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. BIO Stock
  4. Ratings Bio-Rad Laboratories, Inc.